Table 4.
Treatment of patients with peripheral T-cell lymphomas and CNS involvement at presentation or relapse (n = 29).
| Treatment | Initial CNS disease (n = 13 pts) | Secondary CNS relapse (n = 16 pts) |
|---|---|---|
| HD MTX based | 4 | 8 |
| alone | 0 | 1 |
| +cytarabine | 1 | 4 |
| +cytarabine + thiotepa | 1 | 0 |
| +cytarabine + thiotepa + ICE | 1 | 2 |
| +IVE | 1 | 0 |
| +VCR, procarbazine, cytarabine | 0 | 1 |
| Hyper-CVAD/MTX + cytarabine | 1 | 0 |
| MACOP B | 1 | 0 |
| IVAC | 1 | 0 |
| C(H)OP + intrathecal MTX | 6 | 0 |
| ICE | 0 | 3 |
| DHAP/DHAOx | 0 | 2 |
| Brentuximab vedotin | 0 | 1 |
| Gemcitabine/dexamethasone | 0 | 1 |
| Consolidation therapy | ||
| Autologous SCT | 3 | 5 |
| Allogeneic SCT | 1 | 1 |
| WBRT | 2 | 5 |
HD MTX, high-dose methotrexate; ICE, ifosfamide, carboplatin, etoposide; IVE, ifosfamide, epirubicin, etoposide; Hyper-CVAD, cyclophosphamide, vincristine, doxorubicin, dexamethasone; MACOP B, methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin; IVAC, ifosfamide, etoposide, high-dose cytarabine; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; DHAP, dexamethasone, cytarabine, cisplatin; DHAOx, dexamethasone, cytarabine, oxaliplatin; SCT, stem cell transplantation; WBRT, whole brain radiotherapy.